磁力攪拌條件下溶解于10mL雙蒸水中，待固體物質完全溶解，放置冷卻至室溫。將50mg的4-羥甲基苯硼酸頻哪醇酯修飾γ-環糊精衍生物和5mg的2，2，6，6-四甲基哌啶氧化物溶解于5mL甲醇/ 二甲基乙酰胺中。然后在攪拌條件下，將有機相緩慢滴加于水相之中(lmL/min)。滴加完成后，60°C繼續攪拌6h以揮發去除有機溶劑。通過離心分離，用去離子水洗滌，冷凍干燥后即可得到本發明所述的納米藥物。
[0063]實施例15
[0064]首先將4mg卵磷脂和6mg聚乙二醇-二硬脂酰磷脂酰乙醇胺(其中聚乙烯醇的分子量為2000Da)在65°C恒溫磁力攪拌條件下溶解于10mL雙蒸水中，待固體物質完全溶解，放置冷卻至室溫。將50mg的4-羥甲基苯硼酸頻哪醇酯修飾α -環糊精衍生物和5mg的2，2，6，6-四甲基哌啶氧化物溶解于5mL甲醇/N-甲基吡咯烷酮中。然后在攪拌條件下，將有機相緩慢滴加于水相之中(lmL/min)。滴加完成后，60°C繼續攪拌8h以揮發去除有機溶劑。通過離心分離，用去離子水洗滌，冷凍干燥后即可得到本發明所述的納米藥物。
[0065]本發明所述的自由基清除藥物是對炎癥性腸病發揮治療作用的一大類活性物質。在上述實施例中，所采用的藥物為哌啶類氮氧自由基。但是這些氮氧自由基并不限制本發明的保護范圍，本領域普通技術人員可選擇合適的自由基清除藥物。
[0066]參考文獻
[0067]1.Podolsky DK.1nflammatory bowel disease.N Engl J Med 2002 ；347:417-429.
[0068]2.Bouma G，Strober ff.The immunological and genetic basis of inflammatorybowel disease.Nat Rev Immunol 2003;3:521-33.
[0069]3.Khor B，Gardet A,Xavier RJ.Genetics and pathogenesis of inflammatorybowel disease.Nature 2011;474:307-17.
[0070]4.Abraham C，Cho HJ.Mechanisms of disease inflammatory bowel disease.NEngl J Med2009 ；361:2066-2078.
[0071]5.Kaser A, Zeissig S，Blumberg R.1nflammatory bowel disease.Annu RevImmunol2010 ;28:573_621.
[0072]6.Melmed GY，Targan SR.Future b1logic targets for IBD:potentials andpitfalls.Nat Rev Gastroenterol Hepatol 2010 ；7:110-7.
[0073]7.Xavier RJ, Podolsky DK.Unravelling the pathogenesis of inflammatorybowel disease.Nature 2007;448:427-34.
[0074]8.Maloy KJ,Powrie F.1ntestinal homeostasis and its breakdown ininflammatory bowel disease.Nature 2011;474:298-306.
[0075]9.Hanauer SB.Medical therapy for ulcerative colitis 2004.Gastroenterology2004 ；126:1582-92.
[0076]10.Truelove SC.Systemic and local corticosteroid therapy in ulcerativecolitis.Br Med J1960 ；1:464-7.
[0077]11.Ballinger A.Adverse effects of nonsteroidal ant1-1nflammatory drugson the colon.Curr Gastroenterol Rep 2008 ； 10:485-9.
[0078]12.DJ Haens G, Lemmens L，Geboes K，et al.1ntravenous cyclosporine versusintravenous corticosteroids as single therapy for severe attacks of ulcerativecolitis.Gastroenterology2001 ；120:1323-9.
[0079]13.Sandborn WJ, Rutgeerts P，Feagan BG，et al.Colectomy rate comparisonafter treatment of ulcerative colitis with placebo or infliximab.Gastroenterology 2009 ; 137:1250-60 ;quizl520.
[0080]14.Siegel CA, Marden SM, Persing SM，et al.Risk of lymphoma associatedwith combinat1n ant1-tumor necrosis factor and immunomodulator therapy for thetreatment of Crohn’s disease: a meta-analysis.Clin Gastroenterol Hepatol 2009 ；7:874-81.
[0081]15.Van Assche G, Van Ranst M，Sc1t R，et al.Progressive multifocalleukoencephalopathy after natalizumab therapy for Crohn’s disease.N Engl J Med2005 ；353:362-8.
[0082]16.Simmonds NJ，Rampton DS.1nflammatory bowel disease-a radical view.Gutl993 ；34:865-8.
[0083]17.Grisham MB.0xidants and free radicals in inflammatory bowel disease.Lancetl994 ;344:859_61.
[0084]18.Dagli U，Balk M, Yucel D，et al.The role of reactive oxygen metabolitesin ulcerative colitis.1nflamm Bowel Dis 1997 ；3:260-4.
[0085]19.Almenier HA, Al Menshawy HH, Maher MM, et al.0xidative stress andinflammatory bowel disease.Front B1sci 2012 ；4:1335-44.
[0086]20.Babbs CF.0xygen radicals in ulcerative colitis.Free Radic B1l Med1992 ;13:169-181.
[0087]21.Segui J, Gironella M，Sans M，et al.Superoxide dismutase amel1ratesTNBS—induced colitis by reducing oxidative stress,adhes1n moleculeexpress1n, and leukocyte recruitment into the inflamed intestine.J Leukoc B1l2004 ；76:537-44.
[0088]22.Jin Y，Kotakadi VS, Ying L，et al.Americanginseng suppressesinflammat1n and DNA damage associated with mouse colitis.Carcinogenesis 2008 ；29:2351-9.
[0089]23.Lobatto ME, Fuster V，Fayad ZA,et al.Perspectives and opportunitiesfor nanomedicine in the management of atherosclerosis.Nat.Rev.DrugDiscov.